Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
gene	O
in	O
a	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	E-Disease
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
is	O
a	O
recessive	B-Disease
multi	I-Disease
-	I-Disease
system	I-Disease
disorder	E-Disease
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
.	O

The	O
risk	O
of	O
cancer	S-Disease
,	O
especially	O
lymphoid	B-Disease
neoplasias	E-Disease
,	O
is	O
substantially	O
elevated	O
in	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

By	O
analysing	O
tumour	S-Disease
DNA	O
from	O
patients	O
with	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
prolymphocytic	I-Disease
leukaemia	E-Disease
(	O
T	B-Disease
-	I-Disease
PLL	E-Disease
)	O
,	O
a	O
rare	O
clonal	B-Disease
malignancy	E-Disease
with	O
similarities	O
to	O
a	O
mature	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	E-Disease
seen	O
in	O
A	B-Disease
-	I-Disease
T	E-Disease
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B-Disease
-	I-Disease
PLL	E-Disease
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B-Disease
-	I-Disease
T	E-Disease
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	S-Disease
were	O
missense	O
mutations	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O

Two	O
of	O
seventeen	O
mutated	O
T	B-Disease
-	I-Disease
PLL	E-Disease
samples	O
had	O
a	O
previously	O
reported	O
A	B-Disease
-	I-Disease
T	E-Disease
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	S-Disease
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	S-Disease
.	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	S-Disease
DNA	O
from	O
patients	O
with	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkins	I-Disease
lymphomas	E-Disease
(	O
B	B-Disease
-	I-Disease
NHL	E-Disease
)	O
and	O
a	O
B	B-Disease
-	I-Disease
NHL	E-Disease
cell	O
line	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	S-Disease
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
PLL	E-Disease
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	S-Disease
suppressor	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B-Disease
-	I-Disease
PLL	E-Disease
will	O
require	O
further	O
investigation	O
.	O
.	O

Myotonic	B-Disease
dystrophy	E-Disease
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
,	O
the	O
most	O
prevalent	O
muscular	B-Disease
disorder	E-Disease
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	S-Disease
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	E-Disease
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	E-Disease
,	O
tumor	S-Disease
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	S-Disease
predisposition	O
to	O
their	O
offspring	O
.	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	E-Disease
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	S-Disease
tissue	O
.	O

The	O
analysis	O
of	O
tumors	S-Disease
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	S-Disease
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	S-Disease
with	O
LOH	O
.	O

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	S-Disease
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	S-Disease
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	S-Disease
of	O
36	O
patients	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	S-Disease
and	O
the	O
other	O
later	O
developed	O
bilateral	B-Disease
retinoblastoma	E-Disease
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	S-Disease
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
.	O
.	O

Hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	E-Disease
in	O
man	O
.	O

I	O
.	O

Clinical	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	E-Disease
(	O
C5	O
)	O
is	O
described	O
.	O

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	E-Disease
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components	O
.	O

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B-Disease
deficiency	E-Disease
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B-Disease
-	I-Disease
deficient	E-Disease
(	O
C5D	S-Disease
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	S-Disease
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	S-Disease
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	S-Disease
,	O
vasculitis	S-Disease
,	O
and	O
arthritis	S-Disease
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B-Disease
infections	E-Disease
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	S-Disease
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B-Disease
infection	E-Disease
.	O
.	O

Susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	E-Disease
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	E-Disease
(	O
AS	S-Disease
)	O
.	O

METHODS	O
Twins	O
with	O
AS	S-Disease
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B-Disease
Diseases	E-Disease
database	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	S-Disease
.	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	S-Disease
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	S-Disease
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	E-Disease
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	S-Disease
suppressor	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
phase	O
cells	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
tumor	S-Disease
suppression	O
.	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B-Disease
hemochromatosis	E-Disease
(	O
HH	S-Disease
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O
.	O

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

The	O
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	S-Disease
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	S-Disease
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	S-Disease

Autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	E-Disease
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
II	O
.	O

Autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	E-Disease
(	O
ADNDI	S-Disease
)	O
is	O
an	O
inherited	B-Disease
disease	E-Disease
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B-Disease
insipidus	E-Disease
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	S-Disease
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	O
NPII	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B-Disease
inherited	I-Disease
neurodegeneration	E-Disease
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B-Disease
cancer	E-Disease
.	O

Sporadic	B-Disease
prostate	I-Disease
carcinoma	E-Disease
is	O
the	O
most	O
common	O
male	B-Disease
cancer	E-Disease
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	S-Disease
remain	O
to	O
be	O
elucidated	O
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	E-Disease
.	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O

A	O
new	O
tumor	S-Disease
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B-Disease
cancer	E-Disease
cell	O
lines	O
.	O

We	O
screened	O
80	O
prostate	B-Disease
tumors	E-Disease
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	S-Disease
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	E-Disease
.	O
.	O

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B-Disease
disease	E-Disease
.	O

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B-Disease
disease	E-Disease
(	O
HD	S-Disease
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	S-Disease
.	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

With	O
direct	O
tests	O
for	O
the	O
HD	S-Disease
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
.	O
.	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B-Disease
IVA	E-Disease
.	O

Mucopolysaccharidosis	B-Disease
IVA	E-Disease
(	O
MPS	B-Disease
IVA	E-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	E-Disease
caused	O
by	O
a	O
genetic	B-Disease
defect	E-Disease
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B-Disease
IVA	E-Disease
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B-Disease
IVA	E-Disease
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O

4	O
%	O
and	O
10	O
.	O

5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B-Disease
cancer	E-Disease
families	O
and	O
in	O
one	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	E-Disease
family	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
.	O

8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

3	O
and	O
37	O
.	O

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
.	O

2	O
years	O
.	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

Paternal	O
transmission	O
of	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	E-Disease
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B-Disease
retarded	E-Disease
male	O
who	O
suffers	O
severe	O
muscular	B-Disease
weakness	E-Disease
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	S-Disease
.	O

Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	S-Disease
,	O
with	O
onset	O
around	O
30	O
years	O
.	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	E-Disease
have	O
been	O
reported	O
recently	O
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B-Disease
DM	E-Disease
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	S-Disease
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	E-Disease
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B-Disease
DM	E-Disease
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	E-Disease
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	S-Disease
past	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	E-Disease
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	E-Disease
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B-Disease
and	I-Disease
retinal	I-Disease
tumours	E-Disease
of	O
the	O
patient	O
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B-Disease
and	I-Disease
the	I-Disease
pineal	I-Disease
tumours	E-Disease
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O
.	O

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	S-Disease
.	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	S-Disease
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B-Disease
of	I-Disease
hex	I-Disease
A	E-Disease
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	E-Disease
(	O
TSD	S-Disease
)	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O

5	O
%	O
-	O
6	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	S-Disease
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O

Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	S-Disease
mutant	O
.	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	S-Disease
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B-Disease
A	I-Disease
deficiency	E-Disease
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O

The	O
tumor	S-Disease
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	S-Disease
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B-Disease
cancers	E-Disease
.	O

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O

Growth	B-Disease
retardation	E-Disease
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B-Disease
defect	E-Disease
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B-Disease
defect	E-Disease
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	S-Disease
-	O
prone	O
families	O
in	O
France	O
.	O

The	O
French	O
Familial	B-Disease
Melanoma	E-Disease
Study	O
Group	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	S-Disease
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	S-Disease
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B-Disease
melanoma	E-Disease
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	S-Disease
-	O
predisposing	O
gene	O
.	O
.	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B-Disease
dystrophy	E-Disease
patients	O
.	O

The	O
genetic	O
basis	O
of	O
myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	S-Disease
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	S-Disease
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	S-Disease
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B-Disease
dystrophy	E-Disease
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
.	O

Aspartylglucosaminuria	S-Disease
among	O
Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	S-Disease
(	O
AGU	S-Disease
)	O
is	O
a	O
rare	O
disorder	B-Disease
of	I-Disease
glycoprotein	I-Disease
metabolism	E-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
lysosomal	I-Disease
enzyme	I-Disease
aspartylglucosaminidase	E-Disease
(	O
AGA	O
)	O
.	O

AGU	S-Disease
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	S-Disease
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	S-Disease
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
.	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	E-Disease
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	S-Disease
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B-Disease
-	I-Disease
T	E-Disease
but	O
may	O
be	O
cancer	S-Disease
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
,	O
13	O
obligate	O
A	B-Disease
-	I-Disease
T	E-Disease
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B-Disease
-	I-Disease
T	E-Disease
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B-Disease
-	I-Disease
T	E-Disease
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B-Disease
and	I-Disease
sporadic	I-Disease
cancers	E-Disease
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	S-Disease
risk	O
or	O
development	O
.	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B-Disease
cancer	E-Disease
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A	B-Disease
-	I-Disease
T	E-Disease
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
.	O

The	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
tumor	E-Disease
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
inactivation	O
of	O
the	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
tumor	E-Disease
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B-Disease
cancer	I-Disease
syndrome	E-Disease
and	O
is	O
associated	O
with	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	E-Disease
(	O
RCC	S-Disease
)	O
and	O
brain	B-Disease
hemangioblastomas	E-Disease
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	S-Disease
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	S-Disease
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	S-Disease
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	S-Disease
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B-Disease
cancer	E-Disease
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	S-Disease
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	S-Disease
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	S-Disease
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	S-Disease
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	S-Disease
,	O
implicating	O
VHL	S-Disease
as	O
the	O
first	O
tumor	S-Disease
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
.	O
.	O

Piebaldism	S-Disease
with	O
deafness	S-Disease
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	S-Disease
and	O
profound	O
congenital	O
sensorineural	B-Disease
deafness	E-Disease
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

Though	O
auditory	B-Disease
anomalies	E-Disease
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	S-Disease
is	O
not	O
typical	O
in	O
human	O
piebaldism	S-Disease
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B-Disease
deafness	E-Disease
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	S-Disease
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	S-Disease
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B-Disease
syndrome	E-Disease
.	O
.	O

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
.	O

Patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O

5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O

Patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B-Disease
epidermolysis	I-Disease
bullosa	E-Disease
,	O
have	O
generalized	O
blistering	S-Disease
,	O
nail	B-Disease
dystrophy	E-Disease
,	O
patchy	B-Disease
alopecia	E-Disease
,	O
and	O
dental	B-Disease
abnormalities	E-Disease
.	O

Skin	B-Disease
fragility	E-Disease
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	E-Disease
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I	O
.	O

All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O
.	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	S-Disease
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	S-Disease
.	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
5	O
side	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	S-Disease
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	S-Disease
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	S-Disease
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	S-Disease
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	S-Disease
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	S-Disease
remains	O
unknown	O

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	S-Disease
,	O
lymphoma	S-Disease
,	O
and	O
breast	B-Disease
cancer	E-Disease
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B-Disease
degeneration	E-Disease
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B-Disease
-	I-Disease
T	E-Disease
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-Disease
cancer	E-Disease
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	B-Disease
-	I-Disease
T	E-Disease
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B-Disease
degeneration	E-Disease
.	O

This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	S-Disease
,	O
lymphoma	S-Disease
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B-Disease
lymphoma	E-Disease
,	O
mostly	O
in	O
childhood	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B-Disease
dystrophy	E-Disease
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B-Disease
dystrophy	E-Disease
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O

The	O
hemochromatosis	S-Disease
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B-Disease
hemochromatosis	E-Disease
called	O
HFE	O
.	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B-Disease
hemochromatosis	E-Disease
.	O
.	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B-Disease
syndrome	E-Disease
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B-Disease
disomy	E-Disease
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O

6	O
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O

5	O
kb	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B-Disease
disease	E-Disease
and	O
Bannayan	B-Disease
-	I-Disease
Zonana	I-Disease
syndrome	E-Disease
,	O
two	O
hamartoma	B-Disease
syndromes	E-Disease
with	O
germline	O
PTEN	O
mutation	O
.	O

The	O
tumour	S-Disease
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	S-Disease
.	O

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B-Disease
breast	I-Disease
,	I-Disease
brain	I-Disease
,	I-Disease
prostate	I-Disease
and	I-Disease
kidney	I-Disease
cancer	E-Disease
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	S-Disease
such	O
as	O
endometrial	B-Disease
carcinomas	E-Disease
,	O
malignant	B-Disease
melanoma	E-Disease
and	O
thyroid	B-Disease
tumours	E-Disease
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B-Disease
syndromes	E-Disease
Cowden	B-Disease
disease	E-Disease
(	O
CD	S-Disease
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B-Disease
-	I-Disease
Zonana	I-Disease
(	I-Disease
BZS	I-Disease
)	I-Disease
or	I-Disease
Ruvalcaba	I-Disease
-	I-Disease
Riley	I-Disease
-	I-Disease
Smith	I-Disease
syndrome	E-Disease
(	O
MIM	O
153480	O
)	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	S-Disease
families	O
and	O
seven	O
BZS	S-Disease
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	S-Disease
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	S-Disease
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	S-Disease
mutations	O
identified	O
in	O
this	O
exon	O
.	O

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	S-Disease
families	O
studied	O
.	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	S-Disease
families	O
and	O
one	O
BZS	S-Disease
family	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	S-Disease
families	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	S-Disease
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	S-Disease
families	O
with	O
breast	B-Disease
disease	E-Disease
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B-Disease
breast	I-Disease
disease	E-Disease
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	S-Disease
families	O
.	O

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B-Disease
component	I-Disease
C6	I-Disease
deficiency	E-Disease
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B-Disease
component	I-Disease
C6	I-Disease
deficiency	E-Disease
(	O
C6D	S-Disease
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B-Disease
meningitis	E-Disease
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	S-Disease
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	S-Disease
or	O
other	O
neisserial	B-Disease
infection	E-Disease
.	O

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	S-Disease
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

PAX6	O
mutations	O
reviewed	O
.	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	S-Disease
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B-Disease
anomaly	E-Disease
,	O
with	O
congenital	B-Disease
cataracts	E-Disease
,	O
with	O
autosomal	B-Disease
dominant	I-Disease
keratitis	E-Disease
,	O
and	O
with	O
isolated	B-Disease
foveal	I-Disease
hypoplasia	E-Disease
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	S-Disease
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Very	O
nearly	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B-Disease
cancer	E-Disease
families	O
.	O

The	O
Breast	B-Disease
Cancer	E-Disease
Linkage	O
Consortium	O
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B-Disease
breast	I-Disease
cancer	E-Disease
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B-Disease
cancer	E-Disease
,	O
collected	O
by	O
the	O
Breast	B-Disease
Cancer	E-Disease
Linkage	O
Consortium	O
.	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B-Disease
or	I-Disease
other	I-Disease
cancers	E-Disease
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B-Disease
and	I-Disease
female	I-Disease
breast	I-Disease
cancer	E-Disease
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B-Disease
cancer	E-Disease
only	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B-Disease
cancer	E-Disease
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
corresponding	O
ovarian	B-Disease
cancer	E-Disease
risks	O
were	O
0	O
.	O

4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	E-Disease
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B-Disease
movement	I-Disease
abnormalities	E-Disease
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
I	E-Disease
.	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxias	I-Disease
type	I-Disease
I	E-Disease
spinocerebellar	B-Disease
ataxias	I-Disease
1	I-Disease
and	I-Disease
2	E-Disease
(	O
SCA1	S-Disease
,	O
n	O
=	O
11	O
;	O
SCA2	S-Disease
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	S-Disease
/	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	E-Disease
(	O
MJD	S-Disease
)	O
(	O
n	O
=	O
16	O
)	O
.	O

In	O
SCA1	S-Disease
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	S-Disease
.	O

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	O
.	O

In	O
SCA2	S-Disease
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

In	O
SCA3	S-Disease
,	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	E-Disease
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	E-Disease
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	S-Disease
,	O
90	O
%	O
of	O
the	O
SCA2	S-Disease
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	S-Disease
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	S-Disease
,	O
SCA2	S-Disease
,	O
and	O
SCA3	S-Disease
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
.	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	E-Disease
.	O

Ventricular	B-Disease
fibrillation	E-Disease
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	E-Disease
(	O
IVF	S-Disease
)	O
.	O

A	O
distinct	O
group	O
of	O
IVF	S-Disease
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B-Disease
death	E-Disease
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
IVF	S-Disease
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	S-Disease
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	S-Disease
families	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	S-Disease
.	O
.	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B-Disease
IVA	E-Disease
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

Mucopolysaccharidosis	B-Disease
IVA	E-Disease
(	O
MPS	B-Disease
IVA	E-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	E-Disease
caused	O
by	O
a	O
genetic	B-Disease
defect	E-Disease
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B-Disease
IVA	E-Disease
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B-Disease
IVA	E-Disease
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

One	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B-Disease
IVA	E-Disease
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
.	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	E-Disease
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	E-Disease
(	O
DDS	S-Disease
)	O
,	O
or	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	E-Disease
(	O
DMS	S-Disease
)	O
associated	O
with	O
pseudohermaphroditism	S-Disease
and	O
/	O
or	O
Wilms	B-Disease
tumor	E-Disease
(	O
WT	S-Disease
)	O
.	O

Most	O
mutations	O
in	O
DDS	S-Disease
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B-Disease
DMS	E-Disease
(	O
IDMS	S-Disease
)	O
,	O
10	O
with	O
DDS	S-Disease
,	O
and	O
4	O
with	O
urogenital	B-Disease
abnormalities	E-Disease
and	O
/	O
or	O
WT	S-Disease
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	S-Disease
.	O

One	O
male	O
and	O
two	O
female	O
IDMS	S-Disease
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

Two	O
mutations	O
associated	O
with	O
IDMS	S-Disease
are	O
different	O
from	O
those	O
described	O
in	O
DDS	S-Disease
patients	O
.	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	S-Disease
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	S-Disease
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	S-Disease
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
.	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	E-Disease
and	O
in	O
the	O
general	O
population	O
.	O

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
.	O
.	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	S-Disease
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B-Disease
-	I-Disease
overload	I-Disease
disease	E-Disease
hereditary	B-Disease
hemochromatosis	E-Disease
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O

The	O
2	O
.	O

6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	S-Disease
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B-Disease
disease	E-Disease
.	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B-Disease
disease	E-Disease
.	O

Arg778Leu	O
,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O

5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B-Disease
disease	E-Disease
.	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B-Disease
dystrophy	E-Disease
.	O

Myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	S-Disease
gene	O
.	O

One	O
model	O
of	O
DM	S-Disease
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	S-Disease
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	S-Disease
pathogenesis	O
.	O
.	O

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	E-Disease
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	E-Disease
(	O
FNDI	S-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	E-Disease
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	S-Disease
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	S-Disease
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

Genetic	O
heterogeneity	O
of	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	E-Disease
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	E-Disease
,	O
a	O
common	O
autosomal	B-Disease
dominant	I-Disease
condition	E-Disease
of	O
craniosynostosis	S-Disease
and	O
limb	B-Disease
anomalies	E-Disease
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O
.	O

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	E-Disease
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B-Disease
synostosis	E-Disease
,	O
brachycephaly	S-Disease
,	O
low	B-Disease
frontal	I-Disease
hairline	E-Disease
,	O
facial	B-Disease
asymmetry	E-Disease
,	O
ptosis	S-Disease
,	O
hypertelorism	S-Disease
,	O
broad	B-Disease
great	I-Disease
toes	E-Disease
,	O
and	O
clinodactyly	S-Disease
.	O

Significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B-Disease
condition	E-Disease
-	O
such	O
as	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
,	I-Disease
Crouzon	I-Disease
,	I-Disease
and	I-Disease
Pfeiffer	I-Disease
syndromes	E-Disease
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
.	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B-Disease
syndrome	E-Disease
patients	O
.	O

Angelman	B-Disease
syndrome	E-Disease
(	O
AS	S-Disease
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B-Disease
disomy	E-Disease
(	O
UPD	S-Disease
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	S-Disease
individuals	O
or	O
families	O
.	O

Two	O
identical	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	S-Disease
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	S-Disease
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	S-Disease
daughter	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

The	O
hemochromatosis	S-Disease
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

Hemochromatosis	S-Disease
,	O
the	O
inherited	B-Disease
disorder	I-Disease
of	I-Disease
iron	I-Disease
metabolism	E-Disease
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B-Disease
overload	E-Disease
and	O
premature	B-Disease
death	E-Disease
.	O

The	O
hemochromatosis	S-Disease
gene	O
,	O
HFE	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O
.	O

Although	O
hemochromatosis	S-Disease
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O

68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	E-Disease
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	S-Disease
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	E-Disease
(	O
AAPC	S-Disease
)	O
,	O
a	O
variant	O
of	O
familial	B-Disease
adenomatous	I-Disease
polyposis	E-Disease
(	O
FAP	S-Disease
)	O
.	O

AAPC	S-Disease
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B-Disease
adenomas	E-Disease
and	O
a	O
later	O
onset	O
of	O
colorectal	B-Disease
cancer	E-Disease
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	S-Disease
families	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	S-Disease
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	S-Disease
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	S-Disease
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	S-Disease
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B-Disease
adenomas	E-Disease
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	S-Disease
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O

In	O
all	O
AAPC	S-Disease
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B-Disease
adenomas	E-Disease
and	O
rectal	B-Disease
polyp	E-Disease
sparing	O
was	O
observed	O
.	O

No	O
desmoid	B-Disease
tumors	E-Disease
were	O
found	O
in	O
these	O
kindreds	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	S-Disease
families	O
,	O
the	O
location	O
of	O
the	O
APC	S-Disease
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	S-Disease
patients	O
.	O
.	O

Wilms	B-Disease
'	I-Disease
tumor	E-Disease
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B-Disease
tumor	E-Disease
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
MIS	O
expression	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B-Disease
pseudohermaphroditism	E-Disease
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	E-Disease
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
SF	O
-	O
1	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

A	O
mouse	O
model	O
for	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	E-Disease
imprinting	O
-	O
centre	O
mutations	O
.	O

Imprinting	O
in	O
the	O
15q11	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	E-Disease
(	O
PWS	S-Disease
)	O
.	O

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	S-Disease
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	S-Disease
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	S-Disease
infants	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B-Disease
disease	E-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B-Disease
-	I-Disease
T	E-Disease
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

The	O
others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	E-Disease
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	E-Disease
(	O
TSD	S-Disease
)	O
,	O
the	O
fatal	O
infantile	B-Disease
form	I-Disease
of	I-Disease
G	I-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
,	I-Disease
Type	I-Disease
1	E-Disease
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	E-Disease
.	O

On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
TSD	S-Disease
.	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B-Disease
A	I-Disease
enzyme	I-Disease
deficiency	E-Disease
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B-Disease
A	I-Disease
deficiency	E-Disease
in	O
this	O
proband	O
.	O
.	O

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B-Disease
syndrome	E-Disease
.	O

Pendred	B-Disease
syndrome	E-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	E-Disease
characterized	O
by	O
early	O
childhood	O
deafness	S-Disease
and	O
goiter	S-Disease
.	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	S-Disease
gene	O
in	O
patients	O
from	O
14	O
Pendred	S-Disease
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	S-Disease
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

The	O
identification	O
of	O
two	O
frequent	O
PDS	S-Disease
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B-Disease
syndrome	E-Disease
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	S-Disease
gene	O
results	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	E-Disease
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	E-Disease
(	O
XLDCM	S-Disease
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	S-Disease
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B-Disease
involvement	E-Disease
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B-Disease
myopathy	E-Disease
.	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	E-Disease
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	S-Disease
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	S-Disease
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	S-Disease
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	S-Disease
.	O
.	O

Severe	O
early	O
-	O
onset	O
obesity	S-Disease
,	O
adrenal	B-Disease
insufficiency	E-Disease
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B-Disease
deficiency	E-Disease
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	S-Disease
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	S-Disease
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	S-Disease
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B-Disease
deficiency	E-Disease
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	O

Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B-Disease
defect	E-Disease
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B-Disease
endocrine	I-Disease
disorder	E-Disease
resulting	O
in	O
early	O
-	O
onset	O
obesity	S-Disease
,	O
adrenal	B-Disease
insufficiency	E-Disease
and	O
red	O
hair	O
pigmentation	O
.	O
.	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B-Disease
hydroxylase	I-Disease
deficiency	E-Disease
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

Phenylketonuria	S-Disease
(	O
PKU	S-Disease
)	O
and	O
mild	B-Disease
hyperphenylalaninemia	E-Disease
(	O
MHP	S-Disease
)	O
are	O
allelic	B-Disease
disorders	E-Disease
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B-Disease
deficiency	E-Disease
correlate	O
with	O
PAH	O
genotypes	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B-Disease
deficiency	E-Disease
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	S-Disease
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B-Disease
dystrophy	E-Disease
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	S-Disease
and	O
other	O
human	O
genetic	B-Disease
diseases	E-Disease
are	O
unknown	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	S-Disease
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	S-Disease
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
.	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	S-Disease
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	S-Disease
phenotype	O
.	O

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	S-Disease
phenotype	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B-Disease
tumors	E-Disease
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	S-Disease
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O

Maternal	B-Disease
disomy	E-Disease
and	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	E-Disease
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

Maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
(	I-Disease
UPD	I-Disease
)	I-Disease
for	I-Disease
chromosome	I-Disease
15	E-Disease
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	E-Disease
(	O
PWS	S-Disease
)	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B-Disease
disomy	I-Disease
15	E-Disease
in	O
PWS	S-Disease
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
PWS	S-Disease
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	S-Disease
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	S-Disease
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
.	O

B	O
.	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

B	O
.	O

Maternal	B-Disease
disomy	E-Disease
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
.	O

Uniparental	B-Disease
disomy	E-Disease
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	S-Disease
.	O

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B-Disease
UPD	I-Disease
15	E-Disease
and	O
PWS	S-Disease

Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	I-Disease
type	I-Disease
2	E-Disease
and	O
Stuve	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	E-Disease
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	E-Disease
(	O
SJS	S-Disease
)	O
of	O
myotonia	S-Disease
and	O
skeletal	B-Disease
dysplasia	E-Disease
,	O
which	O
we	O
called	O
SJS	B-Disease
type	I-Disease
2	E-Disease
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	E-Disease
(	O
SWS	S-Disease
)	O
,	O
which	O
comprises	O
campomelia	S-Disease
at	O
birth	O
with	O
skeletal	B-Disease
dysplasia	E-Disease
,	O
contractures	S-Disease
,	O
and	O
early	B-Disease
death	E-Disease
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B-Disease
type	I-Disease
2	E-Disease
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	S-Disease
at	O
age	O
7	O
years	O
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	S-Disease
or	O
SWS	S-Disease
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B-Disease
disorder	E-Disease
(	O
with	O
congenital	B-Disease
joint	I-Disease
contractures	E-Disease
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	S-Disease
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B-Disease
-	I-Disease
metaphyseal	I-Disease
skeletal	I-Disease
dysplasia	E-Disease
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B-Disease
dysplasia	E-Disease
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B-Disease
type	I-Disease
2	E-Disease
,	O
one	O
with	O
SWS	S-Disease
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
hypothesis	O
that	O
SWS	S-Disease
and	O
SJS	B-Disease
type	I-Disease
2	E-Disease
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

A	O
mouse	O
model	O
of	O
severe	O
von	B-Disease
Willebrand	I-Disease
disease	E-Disease
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	S-Disease
.	O

von	B-Disease
Willebrand	I-Disease
factor	I-Disease
(	I-Disease
vWf	I-Disease
)	I-Disease
deficiency	E-Disease
causes	O
severe	O
von	B-Disease
Willebrand	I-Disease
disease	E-Disease
in	O
humans	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

vWf	B-Disease
-	I-Disease
deficient	E-Disease
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B-Disease
Willebrand	E-Disease
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O

Defective	O
thrombosis	S-Disease
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B-Disease
injury	E-Disease
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B-Disease
Willebrand	I-Disease
disease	E-Disease
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B-Disease
ovarian	I-Disease
cancer	E-Disease
.	O

Hereditary	B-Disease
Ovarian	I-Disease
Cancer	E-Disease
Clinical	O
Study	O
Group	O
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B-Disease
cancer	E-Disease
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B-Disease
cancer	E-Disease
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B-Disease
forms	I-Disease
of	I-Disease
ovarian	I-Disease
cancer	E-Disease
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B-Disease
ovarian	I-Disease
cancer	E-Disease
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	O
.	O

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B-Disease
cancer	E-Disease
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O

5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B-Disease
cancer	E-Disease
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B-Disease
cancer	E-Disease
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	S-Disease
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	S-Disease
(	O
ALD	S-Disease
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	S-Disease
gene	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	S-Disease
type	O
.	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B-Disease
disease	E-Disease
(	O
AD	S-Disease
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
bilateral	I-Disease
cerebellar	I-Disease
hemispheres	E-Disease
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B-Disease
of	I-Disease
the	I-Disease
cerebral	I-Disease
white	I-Disease
matter	E-Disease
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	S-Disease
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	S-Disease
with	O
phenotypic	O
variations	O
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B-Disease
lesion	E-Disease
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B-Disease
degeneration	E-Disease
in	O
ALD	S-Disease
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
.	O
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B-Disease
C9	I-Disease
deficiency	E-Disease
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	E-Disease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	E-Disease
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B-Disease
deficiency	E-Disease
in	O
four	O
Japanese	O
C9	B-Disease
-	I-Disease
deficient	E-Disease
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B-Disease
meningitis	E-Disease
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9	B-Disease
-	I-Disease
deficient	E-Disease
individuals	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B-Disease
deficiency	E-Disease
.	O
.	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

The	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	E-Disease
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B-Disease
in	I-Disease
BRCA1	E-Disease
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O
.	O

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	S-Disease
,	O
Peters	B-Disease
anomaly	E-Disease
,	O
autosomal	B-Disease
dominant	I-Disease
keratitis	E-Disease
,	O
and	O
familial	B-Disease
foveal	I-Disease
dysplasia	E-Disease
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	S-Disease
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	S-Disease
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	S-Disease
.	O
.	O

Reversal	O
of	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	E-Disease
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
A	I-Disease
dehydrogenase	I-Disease
deficiency	E-Disease
.	O

Very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
A	I-Disease
dehydrogenase	I-Disease
(	I-Disease
VLCAD	I-Disease
)	I-Disease
deficiency	E-Disease
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B-Disease
deficiency	E-Disease
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	E-Disease
,	O
hepatomegaly	S-Disease
,	O
encephalopathy	S-Disease
,	O
and	O
hypotonia	S-Disease
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B-Disease
deficiency	E-Disease
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B-Disease
deficiency	E-Disease
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	S-Disease
in	O
children	O
.	O
.	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	E-Disease
(	O
IDDM	S-Disease
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	S-Disease
.	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

The	O
APC	S-Disease
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B-Disease
tumors	E-Disease
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

Classical	O
familial	B-Disease
adenomatous	I-Disease
polyposis	E-Disease
(	O
FAP	S-Disease
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B-Disease
dominant	I-Disease
disease	E-Disease
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	E-Disease
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	S-Disease
gene	O
.	O

A	O
variant	O
of	O
FAP	S-Disease
is	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	E-Disease
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	S-Disease
gene	O
.	O

Attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	E-Disease
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B-Disease
adenomas	E-Disease
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	S-Disease
.	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	S-Disease
has	O
no	O
mutations	O
in	O
the	O
APC	S-Disease
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	S-Disease
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
tumors	E-Disease
,	O
including	O
multiple	O
adenomas	S-Disease
,	O
in	O
Ashkenazim	O
.	O

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
carcinoma	E-Disease
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	S-Disease
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O

Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colorectum	E-Disease
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	S-Disease
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	E-Disease
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	S-Disease
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B-Disease
cancer	E-Disease
risk	O
in	O
the	O
general	O
population	O
.	O
.	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B-Disease
chloride	I-Disease
diarrhea	E-Disease
(	O
CLD	S-Disease
)	O
gene	O
.	O

Congenital	B-Disease
chloride	I-Disease
diarrhea	E-Disease
(	O
CLD	S-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	S-Disease
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	S-Disease
patients	O
and	O
controls	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	S-Disease
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B-Disease
syndrome	E-Disease
gene	O
(	O
PDS	S-Disease
)	O
.	O
.	O

The	O
APCI1307K	O
allele	O
and	O
cancer	S-Disease
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	E-Disease
(	O
FAP	S-Disease
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B-Disease
dominant	I-Disease
disorder	E-Disease
characterized	O
by	O
multiple	O
intestinal	O
polyps	S-Disease
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B-Disease
cancer	E-Disease
(	O
CRC	S-Disease
)	O
.	O

APC	S-Disease
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	S-Disease
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

The	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	S-Disease
(	O
ref	O
.	O
2	O
)	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	S-Disease
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

Risk	O
of	O
developing	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
other	I-Disease
cancers	E-Disease
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B-Disease
ataxia	E-Disease
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	S-Disease
gene	O
.	O

Friedreich	B-Disease
ataxia	E-Disease
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	S-Disease
gene	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B-Disease
leukodystrophy	E-Disease
.	O

Deficiency	B-Disease
of	I-Disease
arylsulfatase	I-Disease
A	E-Disease
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B-Disease
leukodystrophy	E-Disease
(	O
MLD	S-Disease
)	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	S-Disease
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	S-Disease
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	S-Disease

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B-Disease
cell	I-Disease
carcinoma	E-Disease
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	E-Disease
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	E-Disease
(	O
VHL	S-Disease
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B-Disease
cell	I-Disease
carcinoma	E-Disease
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	S-Disease
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B-Disease
cell	I-Disease
carcinoma	E-Disease
cell	O
lines	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	S-Disease
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	S-Disease
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	S-Disease
cell	O
growth	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B-Disease
mellitus	E-Disease
and	O
optic	B-Disease
atrophy	E-Disease
(	O
Wolfram	B-Disease
syndrome	E-Disease
)	O
.	O

Wolfram	B-Disease
syndrome	E-Disease
(	O
WFS	S-Disease
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disorder	E-Disease
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	E-Disease
and	O
progressive	O
optic	B-Disease
atrophy	E-Disease
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	S-Disease
gene	O
was	O
localized	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	S-Disease
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	S-Disease
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	E-Disease
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	E-Disease
.	O
.	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	E-Disease
(	O
CTX	S-Disease
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O

5	O
%	O
of	O
the	O
normal	O
level	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
sterol	I-Disease
27	I-Disease
-	I-Disease
hydroxylase	I-Disease
activity	E-Disease
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
patients	O
in	O
the	O
Dutch	O
population	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	E-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	E-Disease
(	O
A	B-Disease
-	I-Disease
T	E-Disease
)	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B-Disease
-	I-Disease
T	E-Disease
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Moreover	O
,	O
a	O
16	O
.	O

7	O
-	O
kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B-Disease
-	I-Disease
T	E-Disease
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B-Disease
-	I-Disease
T	E-Disease
founder	O
mutation	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype	O
.	O

All	O
patients	O
manifested	O
classical	O
A	B-Disease
-	I-Disease
T	E-Disease
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	E-Disease
.	O

Autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	E-Disease
is	O
a	O
progressive	O
hematuric	B-Disease
glomerulonephritis	E-Disease
characterized	O
by	O
glomerular	B-Disease
basement	I-Disease
membrane	I-Disease
abnormalities	E-Disease
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	E-Disease
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B-Disease
cancer	E-Disease
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B-Disease
cancer	E-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
from	O
Quebec	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	S-Disease
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O

The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B-Disease
cancer	E-Disease
were	O
also	O
present	O
in	O
the	O
family	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B-Disease
cancer	E-Disease
in	O
the	O
family	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B-Disease
cancer	E-Disease
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B-Disease
cancer	E-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	E-Disease
families	O
.	O

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B-Disease
impairment	E-Disease
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	E-Disease
?	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	E-Disease
(	O
DMD	S-Disease
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B-Disease
impairment	E-Disease
observed	O
in	O
most	O
DMD	S-Disease
patients	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	S-Disease
promoters	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B-Disease
impairment	E-Disease
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B-Disease
dysfunction	E-Disease
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	S-Disease
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B-Disease
impairment	E-Disease
associated	O
with	O
DMD	S-Disease
.	O
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	E-Disease
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	E-Disease
(	O
HNPCC	S-Disease
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
cancer	E-Disease
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O

The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	S-Disease
.	O
.	O

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B-Disease
coproporphyria	E-Disease
family	O
.	O

Hereditary	B-Disease
coproporphyria	E-Disease
(	O
HCP	S-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	E-Disease
characterized	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
coproporphyrinogen	I-Disease
oxidase	E-Disease
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	S-Disease
patients	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
.	O
.	O

Human	B-Disease
complement	I-Disease
factor	I-Disease
H	I-Disease
deficiency	E-Disease
associated	O
with	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	E-Disease
.	O

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
human	I-Disease
complement	I-Disease
regulatory	I-Disease
protein	I-Disease
Factor	I-Disease
H	E-Disease
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B-Disease
renal	I-Disease
disease	E-Disease
.	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	E-Disease
(	O
HUS	S-Disease
)	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

Factor	B-Disease
H	I-Disease
deficiency	E-Disease
is	O
the	O
only	O
complement	B-Disease
deficiency	E-Disease
associated	O
with	O
HUS	S-Disease
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	S-Disease
.	O
.	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B-Disease
dystrophy	E-Disease
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	S-Disease
chromosomes	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	S-Disease
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	S-Disease
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	S-Disease
alleles	O
were	O
always	O
haplotype	O
A	O
.	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	S-Disease
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	S-Disease
and	O
Friedreichs	B-Disease
ataxia	E-Disease
.	O
.	O

The	O
molecular	O
basis	O
of	O
C6	B-Disease
deficiency	E-Disease
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	E-Disease
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Meningococcal	B-Disease
disease	E-Disease
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B-Disease
deficiency	E-Disease
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6	B-Disease
-	I-Disease
deficient	E-Disease
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

Complement	B-Disease
C7	I-Disease
deficiency	E-Disease
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B-Disease
deficiency	E-Disease
are	O
described	O
.	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B-Disease
defects	E-Disease
are	O
tabulated	O
.	O
.	O

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B-Disease
affective	I-Disease
disorder	E-Disease
among	O
the	O
Old	O
Order	O
Amish	O
.	O

Bipolar	B-Disease
affective	I-Disease
disorder	E-Disease
(	O
BPAD	S-Disease
;	O
manic	B-Disease
-	I-Disease
depressive	I-Disease
illness	E-Disease
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	S-Disease
and	O
/	O
or	O
hypomania	S-Disease
interspersed	O
with	O
periods	O
of	O
depression	S-Disease
.	O

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	S-Disease
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	S-Disease
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	S-Disease
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B-Disease
disorders	E-Disease
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B-Disease
disorder	E-Disease
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	S-Disease
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	S-Disease
and	O
perhaps	O
other	O
related	O
affective	B-Disease
disorders	E-Disease
.	O

Segregation	O
distortion	O
in	O
myotonic	B-Disease
dystrophy	E-Disease
.	O

Myotonic	B-Disease
dystrophy	E-Disease
(	O
DM	S-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	E-Disease
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
results	O
in	O
infertility	S-Disease
and	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	E-Disease
(	O
CDM	S-Disease
)	O
with	O
the	O
disappearance	O
of	O
DM	S-Disease
in	O
that	O
pedigree	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	S-Disease
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	S-Disease
in	O
the	O
population	O
.	O

In	O
a	O
survey	O
of	O
DM	S-Disease
in	O
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	S-Disease
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O

7	O
%	O
were	O
affected	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	S-Disease
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	S-Disease
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	S-Disease
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

Diagnosis	O
of	O
hemochromatosis	S-Disease
.	O

If	O
untreated	O
,	O
hemochromatosis	S-Disease
can	O
cause	O
serious	O
illness	O
and	O
early	B-Disease
death	E-Disease
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B-Disease
overload	E-Disease
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	S-Disease
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	S-Disease
is	O
still	O
being	O
evaluated	O
.	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	S-Disease
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	S-Disease
before	O
hepatic	B-Disease
cirrhosis	E-Disease
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
.	O
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	S-Disease
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	E-Disease
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B-Disease
cancer	E-Disease
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307K	O
APC	S-Disease
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B-Disease
cancer	E-Disease
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	E-Disease
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	S-Disease
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B-Disease
cancer	E-Disease
,	O
I1307K	O
was	O
found	O
in	O
5	O
.	O

0	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

6	O
%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
.	O

4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	S-Disease
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	S-Disease
risk	O
.	O

Colorectal	B-Disease
neoplasia	E-Disease
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	S-Disease
.	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B-Disease
,	I-Disease
or	I-Disease
other	I-Disease
,	I-Disease
cancers	E-Disease
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B-Disease
cancer	E-Disease
in	O
European	O
Israelis	O
.	O

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B-Disease
coproporphyria	E-Disease
and	O
mutation	O
update	O
.	O

Hereditary	B-Disease
coproporphyria	E-Disease
(	O
HC	S-Disease
)	O
is	O
an	O
acute	O
hepatic	B-Disease
porphyria	E-Disease
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
coproporphyrinogen	I-Disease
III	I-Disease
oxidase	E-Disease
(	O
CPO	O
)	O
.	O

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B-Disease
dysfunction	E-Disease
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B-Disease
diseases	E-Disease
.	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	S-Disease
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	O
.	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	S-Disease
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B-Disease
defects	E-Disease
reported	O
so	O
far	O
.	O
.	O

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B-Disease
leukodystrophy	E-Disease
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B-Disease
leukodystrophy	E-Disease
(	O
MLD	S-Disease
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	S-Disease
patients	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	S-Disease
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	S-Disease
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	S-Disease
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B-Disease
malignancy	E-Disease
and	O
neurofibromatosis	B-Disease
type	I-Disease
1	E-Disease
.	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	E-Disease
.	O

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	E-Disease
family	O
who	O
developed	O
hematological	B-Disease
malignancy	E-Disease
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B-Disease
type	I-Disease
1	E-Disease
(	O
NF1	S-Disease
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	S-Disease
and	O
/	O
or	O
lymphoma	S-Disease
associated	O
with	O
neurofibromatosis	B-Disease
type	I-Disease
1	E-Disease
.	O
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B-Disease
eye	I-Disease
malformations	E-Disease
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	S-Disease
(	O
congenital	B-Disease
absence	I-Disease
of	I-Disease
the	I-Disease
iris	E-Disease
)	O
,	O
a	O
rare	O
dominant	O
malformation	B-Disease
of	I-Disease
the	I-Disease
eye	E-Disease
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	S-Disease
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	S-Disease
patients	O
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	S-Disease
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B-Disease
pupillae	E-Disease
(	O
displaced	B-Disease
pupils	E-Disease
)	O
and	O
congenital	B-Disease
nystagmus	E-Disease
(	O
searching	B-Disease
gaze	E-Disease
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	S-Disease
phenotypes	O
.	O

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B-Disease
-	I-Disease
related	I-Disease
disease	E-Disease
remains	O
to	O
be	O
uncovered	O
.	O
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	E-Disease
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	E-Disease
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B-Disease
deficiency	E-Disease
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B-Disease
deficiency	E-Disease
were	O
found	O
.	O

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B-Disease
deficiency	E-Disease
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

035	O
.	O

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B-Disease
deficiency	E-Disease
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

04	O
.	O

18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
.	O

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

042	O
.	O

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

04	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B-Disease
deficiency	E-Disease
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B-Disease
deficiency	E-Disease
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B-Disease
deficiency	E-Disease
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B-Disease
deficiency	E-Disease
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	E-Disease
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	E-Disease
(	O
EDMD	S-Disease
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B-Disease
defects	E-Disease
in	O
EDMD	S-Disease
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	S-Disease
.	O

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

In	O
EDMD	S-Disease
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
.	O

Genetic	O
mapping	O
of	O
the	O
copper	B-Disease
toxicosis	E-Disease
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

Abnormal	O
hepatic	B-Disease
copper	I-Disease
accumulation	E-Disease
is	O
recognized	O
as	O
an	O
inherited	B-Disease
disorder	E-Disease
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B-Disease
copper	I-Disease
accumulation	E-Disease
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B-Disease
disease	E-Disease
(	O
WD	S-Disease
)	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B-Disease
overload	E-Disease
disease	O
non	B-Disease
-	I-Disease
Indian	I-Disease
childhood	I-Disease
cirrhosis	E-Disease
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B-Disease
toxicosis	E-Disease
(	O
CT	S-Disease
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B-Disease
disease	E-Disease
.	O

We	O
examined	O
whether	O
the	O
WD	S-Disease
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	S-Disease
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	S-Disease
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
WD	S-Disease
cannot	O
be	O
homologous	O
to	O
CT	S-Disease
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	S-Disease
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O

2	O
-	O
22	O
.	O

5	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
APC	S-Disease
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	S-Disease
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	S-Disease
amino	O
acid	O
changes	O
in	O
colorectal	B-Disease
cancer	E-Disease
predisposition	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B-Disease
cancer	E-Disease
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	E-Disease
(	O
FAP	S-Disease
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B-Disease
polyposis	I-Disease
coli	E-Disease
(	O
APC	S-Disease
)	O
gene	O
mutations	O
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	S-Disease
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	S-Disease
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	E-Disease
.	O

METHODS	O
The	O
APC	S-Disease
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	S-Disease
and	O
15	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	E-Disease
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	S-Disease
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B-Disease
cancer	E-Disease
patients	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	S-Disease
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	S-Disease
and	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	E-Disease
patients	O
.	O
.	O

Inherited	B-Disease
colorectal	I-Disease
polyposis	E-Disease
and	O
cancer	S-Disease
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	S-Disease
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B-Disease
tumor	E-Disease
formation	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
syndrome	E-Disease
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	S-Disease
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	S-Disease
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B-Disease
polyps	E-Disease
and	O
.	O
or	O
colorectal	B-Disease
cancer	I-Disease
,	E-Disease
for	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O

5	O
-	O
1	O
.	O

7	O
for	O
colorectal	B-Disease
neoplasia	E-Disease
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	S-Disease
and	O
colorectal	B-Disease
cancers	E-Disease
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O

We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	S-Disease
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B-Disease
cancer	E-Disease
.	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B-Disease
cancer	E-Disease
prevention	O
in	O
this	O
population	O
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B-Disease
-	I-Disease
inherited	I-Disease
breast	I-Disease
carcinomas	E-Disease
.	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	S-Disease
-	O
suppressor	O
gene	O
and	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	E-Disease
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
cancers	E-Disease
is	O
unclear	O
.	O

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B-Disease
cancers	E-Disease
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	E-Disease
.	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus	O
.	O

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B-Disease
malignancies	E-Disease
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B-Disease
lobular	I-Disease
cancers	E-Disease
and	O
low	B-Disease
-	I-Disease
grade	I-Disease
ductal	I-Disease
carcinomas	E-Disease
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B-Disease
carcinomas	E-Disease
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B-Disease
breast	I-Disease
cancers	E-Disease
.	O
.	O
